DRUG Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own DRUG shares is 12, representing 44.28% of the company's common stock.

RENAISSANCE TECHNOLOGIES LLC, in the last quarter, reduced its stake in DRUG by -59.57% restricting it's holding to 11.2 thousand shares of worth nearly $6.00K. UBS GROUP AG also lessened -80.75% of the DRUG shares from its portfolio, reducing its holding to 2.1 thousand shares of worth $1.20K. SIMPLICITY SOLUTIONS, LLC also shunned DRUG shares holding by -100% last quarter which brought its holding to 0 shares worth -.

As per its latest 13F filing, ADVISORSHARES INVESTMENTS LLC increased its stake in DRUG by 14.73% in the last quarter. The institutional holder raised its holding to 515.32 thousand shares having worth more than $293.78K. TWO SIGMA SECURITIES, LLC also added 100% more shares of DRUG to its portfolio, raising its holding to 16.72 thousand shares of worth $9.53K. ROYAL BANK OF CANADA also increased its DRUG shares holding by 15.95% which brought its holding to 2.41 thousand shares worth $1.00K.

The insider with the most stakes in DRUG is Cormorant Asset Management, LP , 10 percent owner at the company. Additionally, DRUG stock is highly held by N/A N/A and N/A N/A among others.

Company executives, directors, and other insiders own 27.28% percent of Bright Minds Biosciences Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which DRUG insiders have sold stock, totaling 0 shares. Insiders that have sold shares include .

There have been 3 transaction(s) during the past 6-months in which Bright Minds Biosciences Inc. insiders have bought stock, totalling 462171 shares

Around 2.61M Bright Minds Biosciences Inc. shares are held by insiders, which represents about 27.28% of DRUG stock.

DRUG 10 percent owner, Cormorant Asset Management, LP holds the largest portfolio of the company's shares. DRUG shares owned by Cormorant total nearly 1.06 million.

CHECCHI CAPITAL ADVISERS, LLC is the largest institutional owner in DRUG which holds 14.14 thousand shares worth $8.06K or 0.07% of the total DRUG shares outstanding followed by BLACKROCK INC. with ownership of 11.8 thousand shares representing 0.06% of the DRUG ownership. RENAISSANCE TECHNOLOGIES LLC is the third largest stakeholder with 11.2 thousand shares or 0.06% of the ownership worth more than $6.00K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the DRUG is concerned, it is a stock which is not optionable.

Number of DRUG shares short is 221.22K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 6.99M shares of DRUG are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, DRUG has 631.10K shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for DRUG is 1.24.